Experimental study to develop Src-targeted molecular therapy in small cell lung cancer

• Project/Area Number: 22501044
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Clinical oncology
• Research Institution: Tottori University
• Principal Investigator: IGISHI Tadashi 鳥取大学, 医学部, 准教授 (80273895)
• Co-Investigator(Kenkyū-buntansha): MATSUMOT Shingo 独立行政法人国立がん研究センター, 臨床開発センター, 研究員 (10392341) ; HASHIMOTO Kiyoshi 鳥取大学, 医学部附属病院, 助教 (50379640)
• Project Period (FY): 2010 – 2012
• Project Status: Completed (Fiscal Year 2012)
• Budget Amount: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000); Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000); Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
• Keywords: 小細胞肺癌 / 分子標的治療 / Src

Research Abstract

Stem cell factor/c-kit and insulin-like growth factor-I(IGF-I)/IGF-I receptor were detected in small cell lung cancer specimens. In small cell lung cancer cell line, H209 cells, both stem cell factor and IGF-I induced amrubicin resistance. A Src inhibitor, dasatinib, restored the sensitivity to amrubicinin stem cell factor-treated H209 cells. However, dasatinib did not affected IGF-I-induced amrubicinresistance.